Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial

Abstract

We investigated the association of catechol O-methyltransferase (COMT) genotype with abstinence following a smoking cessation attempt among a large cohort of smokers who attempted to quit using either the nicotine transdermal patch or placebo and were followed up over an 8-year period following their initial cessation attempt. In addition, we examined the possible moderating influence of sex on any association. The genotype x treatment interaction effect at 12-week follow-up indicated a greater benefit of active nicotine replacement treatment compared with placebo on likelihood of abstinence in the COMT Met/Met genotype group (33% versus 12%), in comparison to the Met/Val + Val/Val group (22% versus 16%). Our results indicate that COMT genotype may moderate the effect of active transdermal nicotine patch compared with placebo, with reduced relative benefit of nicotine replacement therapy in individuals with Met/Val or Val/Val genotype. Our data follow an emerging pattern of results suggesting that genetic variation in the dopamine pathway may provide a future basis for tailored smoking cessation therapies, but indicate that different genes influencing various components of this pathway may have different effects on response to smoking cessation pharmacotherapy.

Figure 1

Abstinence at 12-wk and 26-wk follow-up, by COMT genotype and treatment group. The proportion of participants abstinent in the active and placebo treatment groups is presented, grouped by COMT genotype. Participants in the Met/Val + Val/Val group seem to derive less benefit from active NRT compared with placebo during the treatment phase (12-wk follow-up) than those in the Met/Met group. This difference has attenuated and is no longer statistically significant at 26-wk follow-up.